歌礼制药-B(01672)宣布其每月一次皮下注射GLP-1R/GIPR双靶点激动剂多肽ASC35治疗肥胖症的I期研究IND获美国FDA批准

智通财经06-23

智通财经APP讯，歌礼制药-B(01672)公布，近期已获得美国食品药品监督管理局(FDA)对其ASC35的I期研究的新药临床试验(IND)批准。ASC35是一款有望成为同类最佳(best-in-class)、每月一次皮下注射的GLP-1受体(GLP-1R)/GIP受体 (GIPR)双靶点激动剂多肽，用于治疗肥胖症。该I期试验是一项随机、双盲、安慰剂对照的临床试验，旨在评估ASC35在84名肥胖(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2645872788?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-23 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645872788","market":"fut","top_or_hot":-1,"title":"歌礼制药-B(01672)宣布其每月一次皮下注射GLP-1R/GIPR双靶点激动剂多肽ASC35治疗肥胖症的I期研究IND获美国FDA批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，歌礼制药-B(01672)公布，近期已获得美国食品药品监督管理局(FDA)对其ASC35的I期研究的新药临床试验(IND)批准。ASC35是一款有望成为同类最佳(best-in-class)、每月一次皮下注射的GLP-1受体(GLP-1R)/GIP受体 (GIPR)双靶点激动剂多肽，用于治疗肥胖症。该I期试验是一项随机、双盲、安慰剂对照的临床试验，旨在评估ASC35在84名肥胖(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1457577.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>歌礼制药-B(01672)宣布其每月一次皮下注射GLP-1R/GIPR双靶点激动剂多肽ASC35治疗肥胖症的I期研究IND获美国FDA批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n歌礼制药-B(01672)宣布其每月一次皮下注射GLP-1R/GIPR双靶点激动剂多肽ASC35治疗肥胖症的I期研究IND获美国FDA批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-23 18:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1457577.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，歌礼制药-B(01672)公布，近期已获得美国食品药品监督管理局(FDA)对其ASC35的I期研究的新药临床试验(IND)批准。ASC35是一款有望成为同类最佳(best-in-class)、每月一次皮下注射的GLP-1受体(GLP-1R)/GIP受体 (GIPR)双靶点激动剂多肽，用于治疗肥胖症。该I期试验是一项随机、双盲、安慰剂对照的临床试验，旨在评估ASC35在84名肥胖(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1457577.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1457577.html","article_id":"2645872788","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645872788","pubTimestamp":1782209049,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，歌礼制药-B 公布，近期已获得美国食品药品监督管理局对其ASC35的I期研究的新药临床试验批准。ASC35是一款有望成为同类最佳、每月一次皮下注射的GLP-1受体/GIP受体 双靶点激动剂多肽，用于治疗肥胖症。体外实验显示，ASC35对GLP-1R和GIPR的激动活性比替尔泊肽强约4倍。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","GLP":"Global Partners Lp","IND":"Xtrackers Nifty 500 India ETF","BK4590":"PTP","BK1161":"生物科技","BK1515":"抗疫概念","BK4144":"石油与天然气的储存和运输","BK1574":"生物医药B类股","01672":"歌礼制药-B","BK4160":"多样化房地产投资信托v","GIPR":"Generation Income Properties Inc.","BK4585":"ETF&股票定投概念","BK1191":"制药","01477":"欧康维视生物-B","BK4588":"碎股"},"translate_title":"Ascletis-B (01672) announced that its monthly subcutaneous injection of GLP-1R/GIPR dual-target agonist peptide ASC35 Phase I study IND for the treatment of obesity has been approved by the US FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1.5,"01672":1.5,"LABU":1.5,"GLP":1.5,"GIPR":1.5,"IND":1.5},"content_text":"智通财经APP讯，歌礼制药-B(01672)公布，近期已获得美国食品药品监督管理局(FDA)对其ASC35的I期研究的新药临床试验(IND)批准。ASC35是一款有望成为同类最佳(best-in-class)、每月一次皮下注射的GLP-1受体(GLP-1R)/GIP受体 (GIPR)双靶点激动剂多肽，用于治疗肥胖症。该I期试验是一项随机、双盲、安慰剂对照的临床试验，旨在评估ASC35在84名肥胖(体重指数(BMI)≥30.0 kg/m²)或伴有体重相关合并症的超重(BMI≥27.0 kg/m²)受试者中，单剂量和多剂量递增给药后的安全性、耐受性、药代动力学和药效动力学。该I期试验分为两部分。A部分为ASC35自组装脂质储库型(SALD)月制剂的单剂量递增(SAD)研究;B部分为ASC35 SALD月制剂对比美国FDA批准的替尔泊肽周制剂的多剂量递增(MAD)头对头研究。体外实验显示，ASC35对GLP-1R和GIPR的激动活性比替尔泊肽强约4倍。结合所有临床前研究，ASC35每毫克多肽的疗效优于替尔泊肽(more efficient on a per-milligram peptide basis)。“利用本公司专有的SALD制剂技术研发的ASC35月制剂获FDA批准开展新药临床试验，是歌礼治疗肥胖症的多肽管线的一项激动人心的重要里程碑，当前，我们正在推进多款每月一次至每季度一次皮下注射的多肽进入临床阶段。”歌礼创始人、董事会主席兼首席执行官吴劲梓博士表示，“ASC35卓越的减重潜力，结合更灵活且对患者友好的每月一次皮下注射方式，将有望解决快速增长的肥胖症市场中未被满足的重大需求。”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645872788","isCrawlerRequest":true}